RU2756506C2 - Галогензамещенное гетероциклическое соединение - Google Patents

Галогензамещенное гетероциклическое соединение Download PDF

Info

Publication number
RU2756506C2
RU2756506C2 RU2018109925A RU2018109925A RU2756506C2 RU 2756506 C2 RU2756506 C2 RU 2756506C2 RU 2018109925 A RU2018109925 A RU 2018109925A RU 2018109925 A RU2018109925 A RU 2018109925A RU 2756506 C2 RU2756506 C2 RU 2756506C2
Authority
RU
Russia
Prior art keywords
amino
thiophen
carbonyl
biphenyl
ethoxy
Prior art date
Application number
RU2018109925A
Other languages
English (en)
Russian (ru)
Other versions
RU2018109925A3 (enExample
RU2018109925A (ru
Inventor
Нориаки ИВАСЕ
Хироси НИСИДА
Макото ОКУДО
Масааки ИТО
Сигеюки КОНО
Масааки МАТОЯМА
Сигеру УСИЯМА
Эйдзи ОКАНАРИ
Хирофуми МАЦУНАГА
Кендзи НИСИКАВА
Томио Кимура
Original Assignee
Убе Индастриз, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Убе Индастриз, Лтд. filed Critical Убе Индастриз, Лтд.
Publication of RU2018109925A publication Critical patent/RU2018109925A/ru
Publication of RU2018109925A3 publication Critical patent/RU2018109925A3/ru
Application granted granted Critical
Publication of RU2756506C2 publication Critical patent/RU2756506C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
RU2018109925A 2012-12-28 2013-12-27 Галогензамещенное гетероциклическое соединение RU2756506C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2012286425 2012-12-28
JP2012-286425 2012-12-28
JP2013097171 2013-05-02
JP2013-097171 2013-05-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2015131139A Division RU2649398C2 (ru) 2012-12-28 2013-12-27 Галогензамещенное гетероциклическое соединение

Publications (3)

Publication Number Publication Date
RU2018109925A RU2018109925A (ru) 2019-02-27
RU2018109925A3 RU2018109925A3 (enExample) 2020-12-03
RU2756506C2 true RU2756506C2 (ru) 2021-10-01

Family

ID=51021433

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2018109925A RU2756506C2 (ru) 2012-12-28 2013-12-27 Галогензамещенное гетероциклическое соединение
RU2015131139A RU2649398C2 (ru) 2012-12-28 2013-12-27 Галогензамещенное гетероциклическое соединение

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2015131139A RU2649398C2 (ru) 2012-12-28 2013-12-27 Галогензамещенное гетероциклическое соединение

Country Status (13)

Country Link
US (2) US10000463B2 (enExample)
EP (2) EP2940013B1 (enExample)
JP (3) JP6176258B2 (enExample)
KR (1) KR102189166B1 (enExample)
CN (2) CN104884447B (enExample)
AU (1) AU2013366898B2 (enExample)
BR (1) BR112015015275B1 (enExample)
CA (1) CA2896701C (enExample)
DK (2) DK3360869T3 (enExample)
ES (2) ES2667798T3 (enExample)
MX (1) MX369801B (enExample)
RU (2) RU2756506C2 (enExample)
WO (1) WO2014104372A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2940013B1 (en) * 2012-12-28 2018-02-21 Ube Industries, Ltd. Halogen-substituted heterocyclic compound
SG11201507459YA (en) 2013-03-15 2015-10-29 Epigen Biosciences Inc Heterocyclic compounds useful in the treatment of disease
JP2014231508A (ja) * 2013-05-02 2014-12-11 宇部興産株式会社 ハロゲン置換へテロ環化合物
WO2015199234A1 (ja) * 2014-06-27 2015-12-30 宇部興産株式会社 ハロゲン置換へテロ環化合物の塩
JPWO2017086430A1 (ja) * 2015-11-20 2018-09-06 宇部興産株式会社 Nashの治療又は予防のための医薬組成物
IL289951B2 (en) * 2019-07-30 2025-10-01 Taisho Pharmaceutical Co Ltd Urea compound as an LPA1 receptor antagonist
CN114728168B (zh) 2019-11-15 2024-04-09 吉利德科学公司 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
CN111909170B (zh) * 2020-09-11 2022-08-12 吉林奥来德光电材料股份有限公司 一种有机电致发光化合物、其制备方法以及包含该有机电致发光化合物的有机电致发光器件
JP7859068B2 (ja) * 2021-01-28 2026-05-15 大正製薬株式会社 Lpa1受容体を拮抗するウレア化合物を有効成分として含有する医薬
AU2022273631B2 (en) 2021-05-11 2025-04-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
KR20240007233A (ko) 2021-05-13 2024-01-16 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
CA3222642A1 (en) 2022-12-12 2024-06-12 Bmic Llc Downstream uses for briquettes and other forms of powder from asphalt shingle waste
WO2026094986A1 (en) * 2024-11-01 2026-05-07 Hilung Inc. Dry powder pharmaceutical composition for inhalation comprising small molecule lpa1 antagonist and process for preparation thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1258484A1 (en) * 2000-02-18 2002-11-20 Kirin Beer Kabushiki Kaisha Novel isoxazole and thiazole compounds and use thereof as drugs
US20060194850A1 (en) * 2003-08-05 2006-08-31 Ajinomoto Co. Inc Novel azole compound
EA201100691A1 (ru) * 2008-12-15 2012-02-28 Амира Фармасьютикалс, Инк. Антагонисты рецепторов лизофосфатидной кислоты
WO2012078593A2 (en) * 2010-12-07 2012-06-14 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and uses thereof
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
WO2012138797A1 (en) * 2011-04-05 2012-10-11 Amira Pharmaceuticals, Inc. 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1364659B1 (en) 2001-02-08 2009-11-11 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
MX2011003383A (es) 2008-09-29 2011-04-21 Lilly Co Eli Modulador selectivo del receptor de estrogeno para el tratamiento de osteoartritis.
GB2470833B (en) 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
JP2013501064A (ja) 2009-08-04 2013-01-10 アミラ ファーマシューティカルス,インコーポレーテッド リゾホスファチジン酸受容体アンタゴニストとしての化合物
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
WO2011091167A2 (en) 2010-01-22 2011-07-28 The General Hospital Corporation Lysophosphatidic acid receptor targeting for scleroderma and other fibrotic diseases
WO2011159635A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist for the treatment of dermal conditions
WO2011159633A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
WO2011159632A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye
CN107721940A (zh) 2010-12-07 2018-02-23 阿米拉制药公司 多环lpa1拮抗剂及其使用
EP2744807A4 (en) 2011-08-15 2015-03-04 Intermune Inc COMPOUNDS AS LYSOPHOSPHIC ACID RECEPTOR ANTAGONISTS
EP2940013B1 (en) * 2012-12-28 2018-02-21 Ube Industries, Ltd. Halogen-substituted heterocyclic compound

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1258484A1 (en) * 2000-02-18 2002-11-20 Kirin Beer Kabushiki Kaisha Novel isoxazole and thiazole compounds and use thereof as drugs
US20060194850A1 (en) * 2003-08-05 2006-08-31 Ajinomoto Co. Inc Novel azole compound
EA201100691A1 (ru) * 2008-12-15 2012-02-28 Амира Фармасьютикалс, Инк. Антагонисты рецепторов лизофосфатидной кислоты
WO2012078593A2 (en) * 2010-12-07 2012-06-14 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and uses thereof
WO2012138797A1 (en) * 2011-04-05 2012-10-11 Amira Pharmaceuticals, Inc. 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors

Also Published As

Publication number Publication date
RU2649398C2 (ru) 2018-04-03
US10000463B2 (en) 2018-06-19
EP2940013A4 (en) 2016-08-03
MX369801B (es) 2019-11-21
CN104884447A (zh) 2015-09-02
JPWO2014104372A1 (ja) 2017-01-19
CA2896701A1 (en) 2014-07-03
JP6569792B2 (ja) 2019-09-04
MX2015008479A (es) 2015-09-23
RU2015131139A (ru) 2017-02-03
EP2940013A1 (en) 2015-11-04
BR112015015275B1 (pt) 2021-12-14
JP2019014739A (ja) 2019-01-31
WO2014104372A1 (ja) 2014-07-03
BR112015015275A8 (pt) 2019-10-22
US20180258062A1 (en) 2018-09-13
US10597375B2 (en) 2020-03-24
JP6176258B2 (ja) 2017-08-09
AU2013366898A1 (en) 2015-08-13
CN107698555A (zh) 2018-02-16
RU2018109925A3 (enExample) 2020-12-03
CN104884447B (zh) 2017-10-10
EP2940013B1 (en) 2018-02-21
US20150376160A1 (en) 2015-12-31
ES2667798T3 (es) 2018-05-14
CA2896701C (en) 2020-10-06
JP2017214410A (ja) 2017-12-07
KR20150100756A (ko) 2015-09-02
DK3360869T3 (da) 2020-10-12
DK2940013T3 (en) 2018-03-26
JP6414286B2 (ja) 2018-10-31
RU2018109925A (ru) 2019-02-27
EP3360869A1 (en) 2018-08-15
EP3360869B1 (en) 2020-07-29
AU2013366898B2 (en) 2017-06-29
BR112015015275A2 (pt) 2017-07-11
CN107698555B (zh) 2020-05-05
KR102189166B1 (ko) 2020-12-09
ES2825031T3 (es) 2021-05-14

Similar Documents

Publication Publication Date Title
US10597375B2 (en) Halogen-substituted heterocyclic compound
US9382197B2 (en) Substituted hydroxamic acids and uses thereof
US10150728B2 (en) Alkylene derivatives
US8034832B2 (en) Gyrase inhibitors and uses thereof
US20100278733A1 (en) Composition for diagnosis of amyloid-related disease
RU2641895C2 (ru) ГЕТЕРОЦИКЛИЛЬНЫЕ ПИРИМИДИНОВЫЕ АНАЛОГИ В КАЧЕСТВЕ ИНГИБИТОРОВ Tук2
US20130310379A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
EP3330256B1 (en) HETEROCYCLIC DERIVATIVE HAVING TrkA-INHIBITING ACTIVITY
US9499533B2 (en) Aromatic 5-membered heterocyclic derivative having TRPV4-Inhibiting activity
US6670367B1 (en) Azinyloxy, and phenoxy-diaryl-carboxylic acid derivatives, their preparation and use as mixed ETA/ETB endothelin receptor antagonists
US12545687B2 (en) Uracil derivatives having virus replication inhibitory activity and pharmaceutical composition comprising the same
US20150246938A1 (en) Novel olefin derivative
KR20170124602A (ko) Hdac8 억제제로서의 알파-신나미드 화합물 및 조성물
KR19990063998A (ko) 아미노산 유도체, 그의 제법 및 엔도테린 길항제로서의 그의 용도
WO2023051261A1 (zh) 一种亚胺类化合物及其应用
US20170253607A1 (en) Long-acting hiv protease inhibitor
US12528790B2 (en) Amide derivative having antiviral activity
US6448248B1 (en) Heterocyclic carboxylic acid derivatives, the production and use thereof as endothelin receptor antagonists
EP2113258A1 (en) Aurone derivative-containing composition for diagnosis
HK1026417A (en) Heterocyclic carboxylic acid derivatives, the production and use thereof as endothelin receptor antagonists